for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck buys rights to NewLink's experimental Ebola vaccine

Nov 24 (Reuters) - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp’s experimental Ebola vaccine.

Merck will have the right to research, develop, manufacture, and distribute the vaccine, rVSV-EBOV, as well as any follow-on products, the companies said in a joint statement.

Financial details were not disclosed.

The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to the drug.

The U.S. National Institutes of Health has announced plans to start a large late-stage study of the vaccine in early 2015. (Reporting by Vidya L Nathan in Bangalore; Editing by Siddharth Cavale)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up